News

HIV treatment with nasal-drop form

Oslo 10.04.2012 – Bionor Pharma ASA (OSE: BIONOR) today announces that the placebo controlled study of nasally administered HIV therapeutic vaccine Vacc-4x in combination with Eurocine Vaccines` Endocine has been…

Vacc-4x phase IIB

Oslo 15.02.2012 – With final review of phase IIb viral load data completed, researchers confirm statistically significant reduction of HIV viral load on Vacc-4x compared to placebo. Bionor Pharma announced…

Successful therapeutic vaccination with Vacc-4x

Successful therapeutic vaccination of HIV patients with Vacc-4x, Bionor Pharma’s peptide-based therapeutic vaccine for HIV-1 infection Bionor Pharma announced today presentation of data from its international multicenter double-blinded placebo-controlled phase…